Saga Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non‑invasive liquid biopsies such as blood samples. Its technologies are based on massively parallel sequencing and digital PCR to detect actionable mutations, stratify patient groups, and monitor treatment response. Applications include patient stratification, companion diagnostics, monitoring response to cancer therapies, identifying disease relapse, and aiding treatment decisions across cancers including breast, non‑small cell lung, colorectal cancer, and acute myeloid leukemia. Led by CEO Lao Saal and based in Lund, Sweden, the company serves pharmaceutical companies, scientists, and biomedical laboratory providers. Saga raised SEK40m (€3.7m, $4.1m) in the disclosed financing and will use the funds to accelerate commercialization of its kits and services, continue product development, and perform prospective clinical studies. Regulatory activities toward laboratory ISO accreditation and the company's first CE‑IVD marked kits are also underway.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2019